Food retention varies quite a bit
In the SURMOUNT-1 study, a phase 3 clinical trial in obese patients, randomized participants in a 1:1:1:1 ratio to tirzepatide (5, 10, 15 mg) or placebo over 72 weeks, significant weight reductions were observed at 72 weeks: 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg, compared to 3.1% for placebo [18]
Side Effect Monitoring & Trends This tool allows users to log various side effects such as nausea, fatigue, and appetite changes
The study sample of 30 adults was drawn from a primary care obesity medicine practice
Upper arms: You can use the back of your upper arm
Patients can also experience increased heart rate due to sympathetic nervous system stimulation by GLP-1 receptor agonists